News Headlines

1. Pace Life Sciences Hosts Grand Opening Of Its Center Of Excellence For Aseptic Fill-Finish Services In Salem, NH 7/2/2025

   Pace® Life Sciences, LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace^®, a Science and Technology Company, builds upon its growth in the pharma and biotech industries by remodeling and expanding its Salem, New Hampshire, site to establish the Center of Excellence for Aseptic Fill-Finish Processing. A grand opening ceremony and open house will be held on July 16, 2025.

2. CAI And ValGenesis Partner To Deliver AI-Enabled Digital Validation For The Life Sciences Industry 7/1/2025

   CAI, a global professional services firm specializing in operational readiness for regulated industries, today announced a strategic partnership with ValGenesis, Inc., a leader in digital validation lifecycle management. Together, the companies will help life sciences organizations modernize validation processes and improve compliance through the power of artificial intelligence. 

3. Lab Oversupply Is Pushing Leasing, Rent and Relocation Down 7/1/2025

   The landscape of the U.S. pharmaceutical lab market is changing, according to JLL’s U.S. Life Sciences Property Report. In addition to the effort to bring pharma manufacturing back to the U.S. ahead of looming tariffs, an oversupply of space and lower tenant demand in large biopharma markets is dropping leasing rates, rent costs and lease duration, among other changes.

4. First Cohort Graduates Biomanufacturing Certification Program At Spokane Colleges 6/30/2025

   Ten students graduated from the inaugural Essentials in Biomanufacturing Certification program on June 26, 2025, at Spokane Colleges. Jubilant HollisterStier (JHS), a contract pharmaceutical manufacturing company, partnered with Spokane Colleges to develop this specialized training program to jumpstart careers in the growing life sciences industry.

5. eXoZymes Selected As Core Industry Partner In $9M NSF-Funded Initiative To Advance Modular Cell-Free Biomanufacturing 6/26/2025

   Today, eXoZymes Inc. ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its role in the Meta-PURE initiative, a $9.2M USD National Science Foundation (NSF) funded project under the CFIRE program aimed at transforming the scalability and accessibility of cell-free systems to expand real-world applications.

6. Porton Advanced And EVA Pharma Sign MOU To Expand CAR T-Cell Therapy Access In The Middle East And Africa 6/26/2025

   Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, and EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, have announced the signing of Memorandum of Understanding (MOU) today, which will see the two organizations collaborating on establishing and strengthening CAR T-cell therapy development and manufacturing capabilities at EVA Pharma's facilities.

7. GenSight Biologics Announces Significant Milestone In New Manufacturing Partnership With Catalent 6/26/2025

   GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ, the Company’s gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropathy (LHON), to its new manufacturing partner, Catalent, Inc.

8. Vector BioMed And Muni Seva Ashram Partner To Bring CAR-T Cell Therapy To Rural India 6/25/2025

   This collaboration positions Vector BioMed as the preferred and exclusive CVDMO partner for KCHRC's cell therapy program, helping expand affordable CAR-T cancer treatment to underserved populations.

9. Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements With Cambrex And Thermo Fisher Scientific For Drug Substance And Drug Product Supply 6/25/2025

   Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the recent execution of agreements for the production of AD04 (0.33 mg ondansetron tablets), supporting both the completion of upcoming clinical trials and the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for the treatment of Alcohol Use Disorder (AUD) in the US.

10. AGC Biologics Expands Cell Therapy Development Operations To Asia To Serve Growing Market Need 6/25/2025

    Today, we announced we will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the latest step in the global expansion of the company’s Global Cell and Gene Technologies Division. The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across all markets, with cell therapy manufacturing now available in three continents (Milan, Italy – Longmont, Colorado, U.S. – Yokohama, Japan).